^ ab“Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor”. BioEssays31 (4): 422–34. (April 2009). doi:10.1002/bies.200800210. PMID19274663.
^“The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling”. Cell40 (4): 747–58. (April 1985). doi:10.1016/0092-8674(85)90334-4. PMID2859121.
^“Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway”. Endocrinology153 (5): 2152–63. (May 2012). doi:10.1210/en.2011-1843. PMID22355074.
^ ab“Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease”. Endocrine Reviews30 (6): 586–623. (October 2009). doi:10.1210/er.2008-0047. PMID19752219.
^“Insight into the molecular basis for the kinetic differences between the two insulin receptor isoforms”. The Biochemical Journal440 (3): 397–403. (December 2011). doi:10.1042/BJ20110550. PMID21838706.
^“Visualization of ligand-induced transmembrane signaling in the full-length human insulin receptor”. The Journal of Cell Biology217 (5): 1643–1649. (May 2018). doi:10.1083/jcb.201711047. PMID29453311.
^ ab“Insulin interactions with its receptors: experimental evidence for negative cooperativity”. Biochemical and Biophysical Research Communications55 (1): 154–61. (November 1973). doi:10.1016/S0006-291X(73)80072-5. PMID4361269.
^“Insulin Receptor-Mediated Stimulation Boosts T Cell Immunity during Inflammation and Infection”. Cell Metabolism. (August 2018). doi:10.1016/j.cmet.2018.08.003. PMID30174303.
^“The Insulin Receptor Plays a Critical Role in T Cell Function and Adaptive Immunity”. Journal of Immunology198 (5): 1910–1920. (March 2017). doi:10.4049/jimmunol.1601011. PMID28115529.
^“Genotype-phenotype correlation in inherited severe insulin resistance”. Human Molecular Genetics11 (12): 1465–75. (June 2002). doi:10.1093/hmg/11.12.1465. PMID12023989.
^“Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit”. Diabetes49 (1): 13–9. (January 2000). doi:10.2337/diabetes.49.1.13. PMID10615944.
^“Identification of Grb10 as a direct substrate for members of the Src tyrosine kinase family”. Oncogene19 (25): 2895–903. (June 2000). doi:10.1038/sj.onc.1203616. PMID10871840.
^“Interaction between the Grb10 SH2 domain and the insulin receptor carboxyl terminus”. The Journal of Biological Chemistry271 (15): 8882–6. (April 1996). doi:10.1074/jbc.271.15.8882. PMID8621530.
^“Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains”. The Journal of Biological Chemistry273 (12): 6860–7. (March 1998). doi:10.1074/jbc.273.12.6860. PMID9506989.
^“Human GRB-IRbeta/GRB10. Splice variants of an insulin and growth factor receptor-binding protein with PH and SH2 domains”. The Journal of Biological Chemistry272 (5): 2659–67. (January 1997). doi:10.1074/jbc.272.5.2659. PMID9006901.
^“Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2”. Oncogene19 (16): 2052–9. (April 2000). doi:10.1038/sj.onc.1203469. PMID10803466.
^“Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action”. The Journal of Biological Chemistry277 (2): 1531–7. (January 2002). doi:10.1074/jbc.M101521200. PMID11606564.
^“Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786”. The Journal of Biological Chemistry271 (11): 5980–3. (March 1996). doi:10.1074/jbc.271.11.5980. PMID8626379.
^“Interaction of MAD2 with the carboxyl terminus of the insulin receptor but not with the IGFIR. Evidence for release from the insulin receptor after activation”. The Journal of Biological Chemistry272 (15): 10035–40. (April 1997). doi:10.1074/jbc.272.15.10035. PMID9092546.
^“Insulin induces specific interaction between insulin receptor and protein kinase C delta in primary cultured skeletal muscle”. Molecular Endocrinology15 (4): 565–74. (April 2001). doi:10.1210/mend.15.4.0612. PMID11266508.
^“Differential effects of tumor necrosis factor-alpha on protein kinase C isoforms alpha and delta mediate inhibition of insulin receptor signaling”. Diabetes51 (6): 1921–30. (June 2002). doi:10.2337/diabetes.51.6.1921. PMID12031982.
^“Insulin receptor kinase phosphorylates protein tyrosine phosphatase containing Src homology 2 regions and modulates its PTPase activity in vitro”. Biochemical and Biophysical Research Communications199 (2): 780–5. (March 1994). doi:10.1006/bbrc.1994.1297. PMID8135823.
^“Adapter function of protein-tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate-1 interaction”. The Journal of Biological Chemistry270 (49): 29189–93. (December 1995). doi:10.1074/jbc.270.49.29189. PMID7493946.
“Insulin-like growth factor II (IGF-II)”. The International Journal of Biochemistry & Cell Biology30 (7): 767–71. (July 1998). doi:10.1016/S1357-2725(98)00048-X. PMID9722981.
“Differential regulation of signaling pathways for insulin and insulin-like growth factor I”. Acta Biochimica Polonica46 (1): 51–60. (1999). PMID10453981.
“The functional significance of Shc in insulin signaling as a substrate of the insulin receptor”. Endocrine Journal47 (4): 373–81. (August 2000). doi:10.1507/endocrj.47.373. PMID11075717.
“Insulin receptor--structural and functional characteristics”. Medical Science Monitor7 (1): 169–77. (2001). PMID11208515.